PIK3CA and neoplasm: We identified the PIK3CA (H1047R) mutations in 32.5% (26/80) of CMT FFPE samples, a significant increase compared to our previous study20, which detected this mutation in 14.3% (10/70) of tumor samples via Sanger sequencing.